Tirzepatide (Mounjaro) Posted or Updated on 27 Dec 2024

Brook Health Centre and Silverstone Surgery along with many surgeries have had queries about the use of Tirzepatide (Mounjaro) for weight loss reasons.  Please see a statement below from our ICB (Integrated Care Board) Teams:

Tirzepatide (Mounjaro) for weight loss is currently categorised as a double red drug on the Northamptonshire Formulary, which will be reviewed as an output of the publication of TA1026. It will remain this way while we work with GP Federations + Lakeside Healthcare to develop models for Primary Care-led implementation, and whilst we await further direction from NHS England on their recommended models of care and any associated funding packages. Unfortunately, this information does not align with the NICE TA release.

We have been instructed that GPs do not prescribe Mounjaro for weight management until we have the pathways in place to enable patients to access the wrap around support required, which will increase their chances of making sustainable change, and the various checkpoints to ensure that patients remain on Mounjaro for an appropriate amount of time.

We also know there is no Tier 3 service in Northamptonshire at present. This is being actively worked on and is an issue being faced around the country.